Bristol-Myers Squibb and Celgene Clear Path for Merger
- Posted by ISPE Boston
- On September 4, 2019
Bristol-Myers Squibb (BMS) has announced that Celgene Corporation, in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen under which Amgen would acquire the global rights to Otezla® (apremilast) for $13.4 billion in cash. BMS previously announced the decision to divest Otezla in connection with the ongoing regulatory approval […]
Read More